<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02380261</url>
  </required_header>
  <id_info>
    <org_study_id>EXR338-P001</org_study_id>
    <nct_id>NCT02380261</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Systane® Lid Wipes in Brazil</brief_title>
  <official_title>Assessment Of The Skin And Ocular Tolerance Of The Product Systane® Lid Wipes (050343-01) And Assessment Of The Study Subject Acceptance, Under Normal Use Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NOVARTIS BIOCIENCIAS S/A</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify the skin and ocular tolerance of the product Systane®
      Lid Wipes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Contact-dermatitis Adverse Reaction</measure>
    <time_frame>Day 21</time_frame>
    <description>Participants were assessed by a dermatologist. Contact-dermatitis adverse reaction was characterized by the presence of one or more of the following symptoms or signs: strong itching sensation, erythema, edema, desquamation, papules or vesicles. Both eyes contributed to the analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Ocular Clinical Signs and Discomfort Sensations</measure>
    <time_frame>Day 21</time_frame>
    <description>Participants were assessed by an ophthalmologist. Ocular clinical signs included palpebral edema, conjunctival edema, orbicular secretion, keratoconus, blepharitis, meibomitis, pterygium, hyperemia, chemosis, keratitis, secretion and lacrimation. Both eyes contributed to the analysis.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Ocular Tolerance</condition>
  <condition>Skin Tolerance</condition>
  <arm_group>
    <arm_group_label>Systane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Systane® Lid Wipes</intervention_name>
    <description>Commercially-marketed, individually-packaged, pre-moistened eyelid wipe for daily cleaning</description>
    <arm_group_label>Systane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must sign informed consent.

          -  Agree to adhere to the procedures and requirements of the study.

          -  Wears makeup daily.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Pregnant or breastfeeding.

          -  Ocular conditions as specified in protocol.

          -  Medical conditions as specified in protocol.

          -  Skin conditions as specified in protocol.

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Biociencias SA</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04636-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <results_first_submitted>August 9, 2016</results_first_submitted>
  <results_first_submitted_qc>September 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2016</results_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 1 study center located in Brazil.</recruitment_details>
      <pre_assignment_details>Thirty-five participants were enrolled in this study. This reporting group includes all enrolled participants (35).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Systane</title>
          <description>Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Systane</title>
          <description>Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Age 18-70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Contact-dermatitis Adverse Reaction</title>
        <description>Participants were assessed by a dermatologist. Contact-dermatitis adverse reaction was characterized by the presence of one or more of the following symptoms or signs: strong itching sensation, erythema, edema, desquamation, papules or vesicles. Both eyes contributed to the analysis.</description>
        <time_frame>Day 21</time_frame>
        <population>This analysis population includes all enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Systane</title>
            <description>Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Contact-dermatitis Adverse Reaction</title>
          <description>Participants were assessed by a dermatologist. Contact-dermatitis adverse reaction was characterized by the presence of one or more of the following symptoms or signs: strong itching sensation, erythema, edema, desquamation, papules or vesicles. Both eyes contributed to the analysis.</description>
          <population>This analysis population includes all enrolled participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Ocular Clinical Signs and Discomfort Sensations</title>
        <description>Participants were assessed by an ophthalmologist. Ocular clinical signs included palpebral edema, conjunctival edema, orbicular secretion, keratoconus, blepharitis, meibomitis, pterygium, hyperemia, chemosis, keratitis, secretion and lacrimation. Both eyes contributed to the analysis.</description>
        <time_frame>Day 21</time_frame>
        <population>This analysis population includes all enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Systane</title>
            <description>Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ocular Clinical Signs and Discomfort Sensations</title>
          <description>Participants were assessed by an ophthalmologist. Ocular clinical signs included palpebral edema, conjunctival edema, orbicular secretion, keratoconus, blepharitis, meibomitis, pterygium, hyperemia, chemosis, keratitis, secretion and lacrimation. Both eyes contributed to the analysis.</description>
          <population>This analysis population includes all enrolled participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected for the duration of participation in the study (up to 21 days). This analysis group includes all enrolled participants. Ocular AEs are presented for both study eye and non-study eye combined.</time_frame>
      <desc>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a product and that does not necessarily have a causal relationship with this treatment. All AEs were obtained as solicited and spontaneous comments from the study participants and through regular investigator assessment throughout the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Systane</title>
          <description>Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dir Clinical Operations - LACAR, GCRA</name_or_title>
      <organization>Alcon, a Novartis company</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

